Wound Care : Therapy for Wounds, Ulcerations, Donor Sites, and Burns
Decubitus Ulcers; Venous Stasis and Diabetic Ulcers; Traumatic
Wounds; Skin Autograft Donor Sites; and Burns
Phenytoin has been used topically to speed the healing of decubitus
ulcers, pressure sores, venous stasis and diabetic ulcers, traumatic
wounds, skin autograft donor sites, and burns. Ketoprofen may be
used to control inflammation and pain, lidocaine provides topical
anesthesia, and pentoxifylline may improve microcirculation at the
wound margins and promote healing of the injured area. Misoprostol,
a prostaglandin analog, is often included in wound care formulations
to promote healing. Debridement of necrotic eschar with 40% urea
paste may also speed healing. Medications which improve capillary
blood flow can be added to a compounded medication to enhance circulation
at the wound margins and promote healing of the injured area.
Topical Phenytoin for Wound Healing
The stimulatory effect of orally administered phenytoin on gingival
tissue prompted its assessment in wound healing. Phenytoin may promote
wound healing by a number of mechanisms, including stimulation of
fibroblast proliferation, facilitation of collagen deposition, glucocorticoid
antagonism, and antibacterial activity. Phenytoin has been used topically
in the healing of pressure sores, venous stasis and diabetic ulcers,
traumatic wounds, skin autograft donor sites, and burns.
Rhodes et al compared the healing of stage II decubitus ulcers with
topically applied phenytoin and two other standard topical treatment
procedures in 47 patients in a long-term care setting. Ulcers were
examined for the presence of healthy granulation tissue, reduction
in surface dimensions, and time to healing. Topical phenytoin therapy
resulted in a shorter time to complete healing and formation of granulation
tissue when compared with DuoDerm dressings or triple antibiotic
ointment applications. The mean time to healing in the phenytoin
group was 35.3 +/- 14.3 days compared with 51.8 +/- 19.6 and 53.8
+/- 8.5 days for the DuoDerm and triple antibiotic ointment groups,
respectively. Healthy granulation tissue in the phenytoin group appeared
within 2 to 7 days in all subjects, compared to 6 to 21 days in the
standard treatment groups. The phenytoin-treated group showed no
detectable serum phenytoin concentrations.
Anstead et al. described a patient with a massive grade IV pressure
ulcer that was unresponsive to conventional treatment, yet responded
rapidly to treatment with topical phenytoin. Song and Cheng reported
phenytoin improved wound breaking strength in normal and radiation-impaired
wounds. The results of their study indicated that topical phenytoin
accelerated normal and irradiation-impaired wound healing by increasing
the number of wound macrophages and improving the macrophage function.
Pendse et al evaluated the effectiveness of topical phenytoin in
healing chronic skin ulcers in a controlled trial of 75 inpatients.
At the end of the fourth week, 29 of 40 phenytoin-treated ulcers
had healed completely versus 10 of 35 controls. They concluded: "topical
phenytoin appears to be an effective, inexpensive, and widely available
therapeutic agent in wound healing."
The effectiveness of topical phenytoin as a wound healing agent
was compared with that of OpSite and a conventional topical antibiotic
dressing (Soframycin) in a controlled study of 60 patients with partial-thickness
skin autograft donor sites on the lower extremities. Mean pain scores
were lower and mean time to complete healing (complete epithelialization)
was best in the phenytoin-treated group (6.2 +/- 1.6 days). Topical
phenytoin compared very favorably with, and in some aspects was superior
to, occlusive dressings.
The efficacy of topical phenytoin in the treatment of diabetic foot
ulcers was evaluated in a controlled inpatient study. Fifty patients
were treated with topical phenytoin, and 50 patients received dry
sterile occlusive dressings. Both groups improved, but the ulcers
treated with topical phenytoin healed more rapidly. Mean time to
complete healing was 21 days with phenytoin and 45 days with control.
No study reported any significant adverse effects secondary to topical
phenytoin therapy.
Phenytoin references:
Ann Pharmacother 2001 Jun;35(6):675-81
Click
here to access the PubMed abstract of this article.
Biochem Pharmacol 1999 May 15;57(10):1085-94
Click
here to access the PubMed abstract of this article.
Ann Pharmacother 1996 Jul-Aug;30(7-8):768-75
Click
here to access the PubMed abstract of this article.
Int J Dermatol 1993 Mar;32(3):214-7
Click
here to access the PubMed abstract of this article.
Chung Hua I Hsueh Tsa Chih 1997 Jan;77(1):54-7
Click
here to access the PubMed abstract of this article.
Burns 1993 Aug;19(4):306-10
Click
here to access the PubMed abstract of this article.
Diabetes Care 1991 Oct;14(10):909-11
Benzoyl Peroxide for Treatment of Decubitus Ulcers
Benzoyl peroxide is a powerful oxidizing agent with broad spectrum
germicidal activity and good liposolubility. Therefore, it may represent
a good agent for prevention of wound infection in areas with high
density of sebaceous glands. Topical treatment of pressure sore with
20% benzoyl peroxide in O/W emulsion yielded very satisfactory results.
In another study, 10% benzoyl peroxide gel was used prophylactically
once a day for 7 days before surgery. The researchers concluded that
topical benzoyl peroxide is an efficacious, harmless, and inexpensive
agent for prevention of wound infections in seborrheic regions.
Med Cutan Ibero Lat Am 1988;16(5):427-9
[Benzoyl peroxide in the treatment of decubitus ulcers].
Fernandez Vozmediano JM, Alonso Blasi N, Almenara Barrios
J, Alonso Trujillo F, Lafuente L
Servicio de Dermatologia, Hospital Clinico Universitario Moreno de Mora, Cadiz.
Click
here to access the PubMed abstract of this article.
J Dermatol Surg Oncol 1994 Aug;20(8):538-40
Utility of topical benzoyl peroxide for prevention of surgical
skin wound infection.
Bencini PL, Galimberti M, Signorini M
Instituto di Clinica Dermatologica I e Dermatologia Pediatrica, Universita
di Milano, Italy.
Click
here to access the PubMed abstract of this article.
Miscellaneous
Arch Dermatol. 2001 Oct;137(10):1288-90
Debridement of necrotic eschar with 40% urea paste speeds
healing of residual limbs and avoids further surgery.
Pelle MT, Miller OF 3rd.
Department of Dermatology, Geisinger Medical Center, 100 N Academy Ave, Danville,
PA 17822, USA.
PMID: 11594851 (no abstract available online)
|